S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:ETON

Eton Pharmaceuticals Stock Forecast, Price & News

$3.53
-0.22 (-5.87%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.48
$3.84
50-Day Range
$3.53
$5.11
52-Week Range
$3.48
$10.30
Volume
293,478 shs
Average Volume
207,856 shs
Market Capitalization
$86.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.35
30 days | 90 days | 365 days | Advanced Chart
Receive ETON News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Eton Pharmaceuticals logo

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Headlines

Eton Pharmaceuticals Reports Third Quarter Financial Results
November 15, 2021 |  finance.yahoo.com
Cerevel Therapeutics Holdings Inc.
July 17, 2021 |  wsj.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ETON
Fax
N/A
Employees
16
Year Founded
N/A

Sales & Book Value

Annual Sales
$40 thousand
Book Value
$0.65 per share

Profitability

Net Income
$-27.97 million
Pretax Margin
-67.52%

Debt

Price-To-Earnings

Miscellaneous

Free Float
22,217,000
Market Cap
$86.86 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
1/22/2022
Next Earnings (Estimated)
3/15/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.09 out of 5 stars

Medical Sector

525th out of 1,418 stocks

Pharmaceutical Preparations Industry

247th out of 684 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -












Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions

Is Eton Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Eton Pharmaceuticals stock.
View analyst ratings for Eton Pharmaceuticals
or view top-rated stocks.

How has Eton Pharmaceuticals' stock been impacted by Coronavirus?

Eton Pharmaceuticals' stock was trading at $4.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ETON stock has decreased by 16.0% and is now trading at $3.53.
View which stocks have been most impacted by COVID-19
.

When is Eton Pharmaceuticals' next earnings date?

Eton Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Eton Pharmaceuticals
.

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.10. The business earned $0.78 million during the quarter, compared to the consensus estimate of $3.05 million. Eton Pharmaceuticals had a negative trailing twelve-month return on equity of 58.04% and a negative net margin of 67.52%. During the same quarter in the prior year, the business earned ($0.31) EPS.
View Eton Pharmaceuticals' earnings history
.

What price target have analysts set for ETON?

2 brokers have issued twelve-month price objectives for Eton Pharmaceuticals' stock. Their forecasts range from $11.00 to $14.00. On average, they expect Eton Pharmaceuticals' stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 254.1% from the stock's current price.
View analysts' price targets for Eton Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eton Pharmaceuticals' key executives?

Eton Pharmaceuticals' management team includes the following people:
  • Sean E. Brynjelsen, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Wilson W. Troutman, Chief Financial Officer, Secretary & Treasurer
  • Scott Grossenbach, Vice President-Sales & Marketing
  • Ingrid Hoos, Senior Vice President-Scientific Affairs
  • Paul Stickler, Senior Vice President-Sales & Marketing

What other stocks do shareholders of Eton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA).

When did Eton Pharmaceuticals IPO?

(ETON) raised $22 million in an IPO on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation served as the underwriter for the IPO.

What is Eton Pharmaceuticals' stock symbol?

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eton Pharmaceuticals' stock price today?

One share of ETON stock can currently be purchased for approximately $3.53.

How much money does Eton Pharmaceuticals make?

Eton Pharmaceuticals has a market capitalization of $86.86 million and generates $40 thousand in revenue each year. The company earns $-27.97 million in net income (profit) each year or ($0.45) on an earnings per share basis.

How many employees does Eton Pharmaceuticals have?

Eton Pharmaceuticals employs 16 workers across the globe.

What is Eton Pharmaceuticals' official website?

The official website for Eton Pharmaceuticals is www.etonpharma.com.

Where are Eton Pharmaceuticals' headquarters?

Eton Pharmaceuticals is headquartered at 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010.

How can I contact Eton Pharmaceuticals?

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at (847) 787-7361 or via email at [email protected].


This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.